Home / Research / BPC-157 origins teardown

Paper-trail teardown · Patents, registries and FDA documents read in full · Sources checked October 16, 2026

Is BPC-157 a healing peptide your stomach already makes? Not exactly, and nearly all the research comes from one lab in Zagreb.

Not in any way anyone has shown. BPC-157 is a synthetic 15-amino-acid peptide. Its sequence comes from a 1989 patent that described a larger stomach-juice protein only by its weight and its first 15 building blocks.[1] We searched all 210,706 human protein sequences in UniProt and found no protein that contains it.[14] About 77% of the 222 BPC-157 papers on PubMed include the same Zagreb pharmacologist as a co-author, and there is still no published, completed randomized trial in people.[13][12]

Why this matters this week

On October 14, 2026 FDA sent an “Interim Access Policy for Compounding Using Certain Peptides” to the White House for review. Its text isn’t public yet.[21] News reports say it could let pharmacies make BPC-157.[25] In July, FDA’s advisory committee voted 8–6–1 in favor of adding BPC-157 to the compounding list, even though FDA’s own reviewers advised against it.[22][5] Posts about BPC-157 on X roughly doubled this week, from 105–161 a day on October 9–12 to 232–250 a day on October 13–15.[24] A line that keeps showing up in those posts, often next to a discount code, is that BPC-157 is “a fragment of something already in your gastric juice.”[24] So we went back to the original documents to see where that claim comes from.

Why we say that

The story starts with a patent, not a paper. In a US patent with a 1989 Yugoslav priority date, Predrag Sikirić and colleagues in Zagreb describe collecting stomach juice from 542 patients and purifying from it a substance they named BPC, short for “Body Protection Compound.” They reported a molecular weight of about 40,000 ± 5,000 daltons, measured by gel filtration, and only a partial sequence from one end of the protein. Those first 15 amino acids are the sequence now sold as BPC-157.[1] The 1993 paper that introduced BPC-157 says the same: a 40,000-dalton gastric juice peptide had been “recently isolated,” and the 15-amino-acid fragment is “thought to be essential for its activity.”[3]

Within three years the inventors themselves were stepping away from the natural protein. A 1992 patent application, which lists the drug company Pliva as assignee, says the natural BPC’s broad activity “can be probably a consequence of undetermined structure or even of insufficient purity or homogeneity of isolated compound BPC.” It calls the protein “obtainable only by difficult procedure from dubious natural source” and claims synthetic 8- to 15-residue peptides instead. BPC-157 is sequence number 2 in that filing.[2]

So “from human gastric juice” is shorthand for “copied from a partial sequence of a protein one lab reported purifying.” We didn’t find that protein in today’s databases. None of the 210,706 human sequences in UniProt contains BPC-157’s sequence, and no stretch of any of them matches more than 9 of its 15 positions.[14] A 2025 review likewise notes it “shows no sequence homology with known intestinal peptides.”[6] That doesn’t prove the parent protein doesn’t exist. Databases miss things, and the original isolate was never fully sequenced in anything we found. It does mean that “your body already makes this” is a claim nobody has confirmed.

One lab wrote most of the research

We pulled every PubMed record that mentions BPC-157 in its title or abstract: 222 in all. Of those, 171 list Sikirić as an author. Through the end of 2024 the share was 157 of 176, or 89%.[13] The picture changed only in the last two years. In 2025 and 2026 so far, outside authors wrote 32 of the 46 records, but 20 of those 32 are reviews or commentaries rather than new experiments.[13] PubMed tags none of the 222 as a clinical trial or randomized controlled trial.[13]

A literature dominated by one group isn’t automatically wrong. It does mean the usual check, other labs repeating the work and getting the same answer, has barely happened. A few independent groups have tested it. In lab dishes, a Taiwanese team found BPC-157 helped rat tendon cells grow out of tissue samples, survive stress and migrate.[15] A Chinese team measured how rats and dogs handle it: it breaks down fast, with a half-life under 30 minutes.[16] And in the newest independent animal test, a 2026 Istanbul study of repaired rat Achilles tendons, BPC-157 scored numerically better than controls but didn’t reach statistical significance on the main tissue scores, while TB-500 did.[26]

The paper trail

What the human evidence actually is

A systematic review published October 8, 2026 searched four databases through June 2026. It found three human studies with 30 people in total, none with a control group. It rated the certainty of evidence “very low” and concluded BPC-157 “should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials.”[12] The review covered orthopaedic and regenerative uses, so it left out the older colitis work, which FDA found and summarized.[5]

Sources: colitis trial as summarized by FDA[5]; knee[9]; cystitis[10]; IV[11]; Phase 1 registry[7]. All three Florida reports share a first author and appeared in the same journal.[9][10][11]

Real trials are finally on the way. A 120-person, double-blind, placebo-controlled Phase 2 in hamstring strains has been recruiting in Shenzhen since February 2026, and a 30-person rotator-cuff pilot at the University of Arkansas is set to start in January 2027.[18][19] A 40-person single-arm study of BPC-157 gummies, sponsored by the company selling them, finished in November 2025 without posting results.[20]

What BPC-157 has going for it

To be fair, the animal record is large and strikingly consistent. Across rats and other species, BPC-157 has been reported to protect the stomach, liver and gut and to speed healing of tendon, ligament, muscle and bone, often at microgram-per-kilogram doses.[3][6] FDA’s reviewers summarized the same pattern in rodents.[5] Independent labs in Taiwan and Turkey have seen effects in the same direction in tendon cells and repaired rat tendons, though weaker in the Turkish study.[15][26] A published toxicology package found it wasn’t mutagenic and didn’t cause birth defects in pregnant rats.[5] And the three small human reports, for what they’re worth, didn’t describe treatment-related harms.[12] If the Shenzhen trial runs as registered, it will be the first blinded, placebo-controlled test of BPC-157 for an injury in people.[18]

Side effects and safety

What FDA found is mostly what’s missing. There are no carcinogenicity studies and no complete reproductive studies. There is no human pharmacokinetic data for the oral, injected, nasal or skin routes people actually use.[5] In 28-day injection studies in rats and dogs, FDA flagged changes in clotting times and liver-related signals (higher ALT, glucose and triglycerides) and noted that longer studies were unavailable.[5]

FDA’s adverse-event database held three reports through December 2025. One was injection-site redness and swelling. One was shortness of breath leading to an emergency room visit. In the third, a woman using a “research purposes only” BPC-157 plus TB-500 product developed skin and gum darkening, and it came back when she took the product again.[5] Compounders under section 503A generally don’t report adverse events to FDA, so these numbers say little about how often problems happen.[5]

Two more concerns come up repeatedly. First, BPC-157 is promoted for growing new blood vessels, and a 2017 study tied its effect to VEGFR2, a key receptor for blood-vessel growth.[17] The same process feeds tumors, which is why a 2025 review called for safety work on it.[6] No one has shown that BPC-157 causes or worsens cancer. No one has tested it either. Second, FDA lists BPC-157 among compounding substances that may pose significant safety risks. The agency cites possible immune reactions, peptide impurities and trouble characterizing the ingredient.[23][5]

Where it stands now

BPC-157 is not an FDA-approved drug. In July, FDA’s Pharmacy Compounding Advisory Committee voted to add it to the 503A bulk list over FDA staff objections. On October 14, an interim compounding policy that reportedly covers it reached the White House, and its final text isn’t public.[22][5][21] Even if pharmacies get a legal route, that is a supply decision. It wouldn’t show that the peptide works. For the full regulatory picture, see our FDA peptide policy explainer.

Bottom line: BPC-157 isn’t a known human stomach peptide. It is a synthetic copy of a partial sequence from a protein one lab reported isolating in 1989 and later called a “dubious natural source.”[1][2] Three decades of mostly single-lab animal work look promising. The human evidence is one null colitis abstract and 30 uncontrolled patients.[5][12] The first serious placebo-controlled trial is underway now, and that is the result worth waiting for.[18]

This page analyzes patents, trial registries, regulatory documents and published research. It is not medical advice and does not recommend using, sourcing, or dosing BPC-157. Counts and the proteome scan are Jabbit’s own analyses; the scripts and inputs are cited above.